| pubmed-article:2029994 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2029994 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:2029994 | lifeskim:mentions | umls-concept:C0019080 | lld:lifeskim |
| pubmed-article:2029994 | lifeskim:mentions | umls-concept:C0020541 | lld:lifeskim |
| pubmed-article:2029994 | lifeskim:mentions | umls-concept:C0042345 | lld:lifeskim |
| pubmed-article:2029994 | lifeskim:mentions | umls-concept:C0033497 | lld:lifeskim |
| pubmed-article:2029994 | lifeskim:mentions | umls-concept:C1708528 | lld:lifeskim |
| pubmed-article:2029994 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:2029994 | lifeskim:mentions | umls-concept:C0206034 | lld:lifeskim |
| pubmed-article:2029994 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:2029994 | pubmed:dateCreated | 1991-6-17 | lld:pubmed |
| pubmed-article:2029994 | pubmed:abstractText | To assess the effectiveness of propranolol in the prevention of initial variceal hemorrhage, a double-blind, randomized trial was carried out in three centers. Patients with cirrhosis (78% alcoholic), hepatic venous pressure gradients greater than 12 mm Hg and endoscopically proven esophageal varices were randomly assigned to propranolol (51 patients) or placebo (51 patients). Of the 102 patients, 58% were Child's class A, 34% were Child's class B and 8% were Child's class C. Daily dosage was determined by the administration of progressively increasing doses of propranolol with the hepatic vein catheter in place to achieve a 25% decrease in hepatic venous pressure gradient, a decrease in hepatic venous pressure gradient to less than 12 mm Hg or a decrease in resting heart rate to less than 55 beats/min. During a mean follow-up period of 16.3 mo, 11 patients in the placebo group (22%) bled from esophageal varices compared with 2 in the propranolol group (4%) during a mean period of 17.1 mo (p less than 0.01). Three additional patients (6%) in the placebo group bled from portal hypertensive gastropathy compared with none in the propranolol group. Propranolol appeared effective in preventing bleeding from large varices. Eleven deaths (22%) occurred in the placebo group compared with eight deaths (16%) in the propranolol group (NS). The mean dose of propranolol was 132 mg/day, and the median dose was 80 mg/day. Using a compliance index (pill count, clinic attendance, alcohol and propranolol levels and alcohol history), 81% of the propranolol patients and 77% of the placebo patients were considered compliant. Complications severe enough to require cessation of therapy occurred in eight patients (16%) in the propranolol group and four in the placebo group (8%) (NS). We conclude that propranolol effectively prevents the first variceal hemorrhage in patients with alcoholic cirrhosis and large esophageal varices but does not improve survival. | lld:pubmed |
| pubmed-article:2029994 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2029994 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2029994 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2029994 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2029994 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2029994 | pubmed:month | May | lld:pubmed |
| pubmed-article:2029994 | pubmed:issn | 0270-9139 | lld:pubmed |
| pubmed-article:2029994 | pubmed:author | pubmed-author:BoschJJ | lld:pubmed |
| pubmed-article:2029994 | pubmed:author | pubmed-author:FisherR LRL | lld:pubmed |
| pubmed-article:2029994 | pubmed:author | pubmed-author:GraceN DND | lld:pubmed |
| pubmed-article:2029994 | pubmed:author | pubmed-author:ConnH OHO | lld:pubmed |
| pubmed-article:2029994 | pubmed:author | pubmed-author:MatloffD SDS | lld:pubmed |
| pubmed-article:2029994 | pubmed:author | pubmed-author:RodésJJ | lld:pubmed |
| pubmed-article:2029994 | pubmed:author | pubmed-author:GroszmannR... | lld:pubmed |
| pubmed-article:2029994 | pubmed:author | pubmed-author:WrightS CSC | lld:pubmed |
| pubmed-article:2029994 | pubmed:author | pubmed-author:NavasaMM | lld:pubmed |
| pubmed-article:2029994 | pubmed:author | pubmed-author:Garcia-TsaoGG | lld:pubmed |
| pubmed-article:2029994 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2029994 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:2029994 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2029994 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:2029994 | pubmed:pagination | 902-12 | lld:pubmed |
| pubmed-article:2029994 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:meshHeading | pubmed-meshheading:2029994-... | lld:pubmed |
| pubmed-article:2029994 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:2029994 | pubmed:articleTitle | Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. | lld:pubmed |
| pubmed-article:2029994 | pubmed:affiliation | Medical Service, West Haven Veterans Administration Medical Center, Yale University School of Medicine, Connecticut 06516. | lld:pubmed |
| pubmed-article:2029994 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2029994 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2029994 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:2029994 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:2029994 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:2029994 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2029994 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2029994 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2029994 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2029994 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2029994 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2029994 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2029994 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2029994 | lld:pubmed |
